What is your brain tumor story? Click here to share it. Your story matters.
Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.
**Sponsored Content**
Learn more about Biodexa’s Phase 1 clinical trial investigating the effectiveness of an approved blood cancer drug in liquid form to treat recurrent glioblastoma (GBM).
A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”
Always free for patients & caregivers
